NYSE
$0.4171▲ 0.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.9MShares out 4.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
2- 9.16Pre-market26.09.16 21:308-KKey event#●●●#●●●#●●●
ORAGENICS INC
Oragenics' Chief Medical Officer, Dr. James P. Kelly, is scheduled to present the clinical development progress of the concussion therapeutic candidate ONP-002 at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The presentation will cover the design of the ongoing Phase IIa trial in Australia and the company's anticipated path for IND submission for U.S. clinical development.…more
$0.4171+0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.28After-hours26.08.29 06:068-KKey event
ORAGENICS INC
Oragenics received a delisting notice from the NYSE American on August 26, 2026, due to failure to meet continued listing standards regarding stockholders' equity. The company reported $3.7 million in stockholders' equity as of June 30, 2026, falling below the required thresholds, and must submit a compliance plan by September 25, 2026, to regain compliance by February 25, 2028.…more
$0.4171+0.55%vs prev closeView filingShare
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.16Pre-market26.09.16 21:30#●●●#●●●
Oragenics to Present Clinical Progress of Concussion Treatment ONP-002
Oragenics' Chief Medical Officer will present the clinical development and intranasal delivery platform for its concussion treatment candidate, ONP-002, at an upcoming industry forum. The company is currently conducting Phase IIa trials in Australia and plans to submit an IND application in the U.S. by the end of 2026.…more
$0.4171+0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.28After-hours26.08.29 05:28
●●●●●●●● ●●●●● ●●●●●●
Oragenics is progressing with its Phase IIa clinical trial for brain therapeutics, but has received a deficiency letter from the NYSE American regarding listing standards. The company must submit a compliance plan within 45 days to avoid potential delisting procedures.…more
$0.4171+0.55%vs prev closeShareBenzinga - 8.28After-hours26.08.29 05:25
●●●●●●●● ●●●●● ●●●●●●
Oragenics continues its Phase IIa clinical trial for a concussion treatment, but has received a deficiency notice from the NYSE American regarding stockholders' equity requirements. The company plans to submit a compliance plan, though the risk of delisting remains a significant concern.…more
$0.4171+0.55%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report